CD52 and B-cell chronic lymphocytic leukemia: For instance, alemtuzumab, a humanized, IgG1 kappa monoclonal antibody, recognizes the cell surface glycoprotein CD52 expressed on normal and malignant cells and is used in the therapeutic management of chronic lymphocytic leukemia (CLL) (Demko et al. 2008; Robak 2008).